Epilepsy – Praxis PRAX-628-322

Participating in a clinical trial with Profound means making a real difference in the lives of others facing similar health challenges.

A multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of vormatrigine in adults with focal seizures (POWER2)

Inclusion Criteria:

• Has a diagnosis of focal onset epilepsy according to the International League Against Epilepsy Classification of Epilepsy (2017).
• Prior to randomization, past evidence by CT or MRI that has ruled out a progressive cause of epilepsy in the judgement of the investigator and/or in consultation with the medical monitor.
• Participant must attest to be taking stable doses of 1 or up to 3 acceptable ASMs for at least 4 weeks prior to screening and during screening prior to Day 1.
• Has at least 4 countable focal onset seizures during the 4 weeks of Observation Period immediately prior to randomization with no more than 21 days seizure free during this period.
• Seizure diary must be completed for ≥80% days in the Observation Period.
• Other criteria may apply

Call us at 619-489-5613 or complete the form and our team will reach out soon to help determine your eligibility.